133 related articles for article (PubMed ID: 8342558)
1. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine.
Robertson MJ; Tantravahi R; Griffin JD; Canellos GP; Cannistra SA
Am J Hematol; 1993 Jun; 43(2):95-102. PubMed ID: 8342558
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
Montefusco E; Petti MC; Alimena G; Latagliata R; Celesti F; Capria S; Amadori S; Avvisati G; Mandelli F
Ann Oncol; 1997 Feb; 8(2):175-9. PubMed ID: 9093727
[TBL] [Abstract][Full Text] [Related]
7. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
[TBL] [Abstract][Full Text] [Related]
8. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
9. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Stone RM; Donohue KA; Stock W; Hars V; Linker CA; Shea T; Deangelo DJ; Marcucci G; Bloomfield CD; Larson RA;
Cancer Chemother Pharmacol; 2009 Apr; 63(5):859-64. PubMed ID: 18670778
[TBL] [Abstract][Full Text] [Related]
11. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
[TBL] [Abstract][Full Text] [Related]
12. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
Saven A; Piro LD; Lemon RH; Figueroa ML; Kosty M; Ellison DJ; Beutler E
Cancer; 1994 Jun; 73(12):2953-63. PubMed ID: 7911068
[TBL] [Abstract][Full Text] [Related]
13. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
[TBL] [Abstract][Full Text] [Related]
14. A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.
Kolitz JE; Kempin SJ; Schluger A; Wong GY; Berman E; Jhanwar S; Arlin ZA; Gee T; Clarkson BD
Semin Oncol; 1992 Jun; 19(3 Suppl 9):27-33. PubMed ID: 1641654
[TBL] [Abstract][Full Text] [Related]
15. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
16. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
[TBL] [Abstract][Full Text] [Related]
17. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients.
Ferrajoli A; Liberati AM; Caricchi P; Donti E; Morra E; Lazzarino M; Betti AR; Bernasconi P; Saglio G
Eur J Haematol; 1995 Sep; 55(3):184-8. PubMed ID: 7672091
[TBL] [Abstract][Full Text] [Related]
19. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
[TBL] [Abstract][Full Text] [Related]
20. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Kantarjian HM; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios MB; Smith TL; Calvert L; Deisseroth AB
J Clin Oncol; 1995 Mar; 13(3):553-9. PubMed ID: 7884415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
